Welcome to our dedicated page for Guardion Health Sciences news (Ticker: GHSI), a resource for investors and traders seeking the latest updates and insights on Guardion Health Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardion Health Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardion Health Sciences's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Guardion Health Sciences, Inc. (Nasdaq: GHSI) reported strong financial results for the year ended December 31, 2022, showing revenues of $11.05 million, a 52.8% increase from $7.23 million in 2021, primarily driven by its Viactiv product line, which accounted for 96% of total revenues. Gross profit rose to $4.52 million, up from $3.11 million, although gross margin decreased to 40.9% from 43.0% due to rising operational costs. The company's loss from operations decreased to $(17.42 million) from $(24.75 million) in 2021, and net loss per share improved to $(14.15) compared to $(52.23). As of year-end, the company held $10.66 million in cash. A strategic review is underway to maximize shareholder value, indicating potential changes in the company's direction.
Guardion Health Sciences, Inc. (Nasdaq: GHSI) has engaged Alantra, LLC as its financial advisor for a strategic review and potential transactions. The company's Board of Directors believes the current market valuation does not reflect its value.
Chairman Robert N. Weingarten emphasized the need to explore options that could enhance stockholder value, including the potential sale of the company or its Viactiv brand. CEO Bret Scholtes acknowledged the company's progress since acquiring Viactiv but recognized the necessity of considering strategic measures in response to current market conditions. No specific timeline for the review has been set, and uncertainty remains regarding the outcomes of this process.
Guardion Health Sciences (GHSI) announced on January 24, 2023, that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. This follows a notice from Nasdaq on January 25, 2022, indicating that GHSI's stock had fallen below the required threshold. The compliance was confirmed after GHSI maintained a closing bid price of $1.00 or higher for ten consecutive trading days, from January 9 to January 23, 2023. This achievement allows GHSI to continue its listing on Nasdaq, reaffirming its position in the clinical nutrition market.
Guardion Health Sciences, Inc. (NASDAQ: GHSI) announced a 1-for-50 reverse stock split effective January 6, 2023. This decision, approved by stockholders on January 5, aims to comply with Nasdaq's minimum bid price requirement. The new CUSIP number will be 40145Q500, and approximately 1,232,016 shares will remain outstanding post-split. Despite the action, the company cautions that it may not maintain compliance with Nasdaq requirements in the future. Further details are available in the definitive proxy statement filed with the SEC on December 12, 2022.
Guardion Health Sciences (Nasdaq: GHSI) announced a securities purchase agreement with institutional investors to acquire 495,000 shares of Series C convertible redeemable preferred stock and 5,000 shares of Series D non-convertible redeemable preferred stock at $9.50 per share, raising approximately $4.75 million. The Series C shares can convert into common stock at $0.15768 per share, contingent on stockholder approval for a reverse stock split. Holders of preferred stock can vote on this proposal, and the offering expects to close on November 29, 2022.